Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data

Table 4 Adjusted odds ratios and 95% confidence intervals for prescribing vs. not prescribing a drug based on receiving any payment vs. no payment from the manufacturer making the drug^a

Drug	Manufacturer	Odds Ratio	95% Confidence Interval
Lovastatin ER	Actavis (Andrx)	2.59	0.93–7.18
Almotriptan	Janssen	1.40	0.75–2.61
Amlodipine+olmesartan	Daiichi-Sankyo	2.40	2.29–2.52
Ibuprofen+famotidine	Horizon	8.06	5.42–12.00
Saxagliptin+metformin	AstraZeneca	2.21	2.10–2.34
Naproxen+esomeprazole	Horizon	5.96	5.08–7.00

^aadjusted for gender, specialty, region, therapeutic category and overall prescribing volume
p-value <0.05 are presented in boldface

ISSN: 1472-6963